Verrica Pharmaceuticals (VRCA) Total Debt (2017 - 2025)
Verrica Pharmaceuticals (VRCA) posted quarterly Total Debt of $34.1 million for Q3 2025, down 21.31% year-over-year from $43.3 million in Q3 2024, and down 8.52% quarter-over-quarter from $37.3 million in Q2 2025.
Verrica Pharmaceuticals (VRCA) Total Debt (2017 - 2025) Analysis & Trends
Verrica Pharmaceuticals' Total Debt history runs 9 years deep, the most recent figure standing at $34.1 million for Q3 2025.
- In Q3 2025, Total Debt fell 21.31% year-over-year to $34.1 million; the TTM figure through Sep 2025 stood at $34.1 million (down 21.31% YoY), while the FY2024 annual figure was $43.9 million, up 2.44% from the prior year.
- Total Debt for Q3 2025 stood at $34.1 million, down from $37.3 million in the prior quarter.
- The five-year high for Total Debt was $43.9 million in Q4 2024, with the low at $34.1 million in Q3 2025.
- The 5-year median for Total Debt is $42.0 million (2022), against an average of $41.3 million.
- The sharpest annual moves came in 2021 and 2025: Total Debt advanced 18.2% in 2021, then declined 21.31% in 2025.
- Verrica Pharmaceuticals' Total Debt stood at $41.7 million in 2021, then gained by 1.44% to $42.3 million in 2022, then advanced by 1.37% to $42.9 million in 2023, then increased by 2.44% to $43.9 million in 2024, then retreated by 22.41% to $34.1 million in 2025.
- Business Quant data shows VRCA's Total Debt at $34.1 million in Q3 2025, $37.3 million in Q2 2025, and $40.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Verrica Pharmaceuticals | 104.71 Mn | 93.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 34.08 Mn |
| Jun 30, 2025 | 37.25 Mn |
| Mar 31, 2025 | 40.63 Mn |
| Dec 31, 2024 | 43.92 Mn |
| Sep 30, 2024 | 43.31 Mn |
| Jun 30, 2024 | 42.75 Mn |
| Mar 31, 2024 | 42.85 Mn |
| Dec 31, 2023 | 42.87 Mn |
| Sep 30, 2023 | 42.40 Mn |
| Jun 30, 2022 | 42.29 Mn |
| Mar 31, 2022 | 42.00 Mn |
| Dec 31, 2021 | 41.69 Mn |
| Sep 30, 2021 | 41.35 Mn |
| Jun 30, 2021 | 41.01 Mn |
| Mar 31, 2021 | 40.67 Mn |
| Dec 31, 2020 | 35.32 Mn |
| Sep 30, 2020 | 34.98 Mn |
| Jun 30, 2020 | 34.72 Mn |
| Mar 31, 2020 | 34.43 Mn |
| Jun 30, 2019 | 6,000.00 |